Showing results (241-250 of 293) with videos related to

Sort By:
Pageof 30
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 5, 2019
Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using 89Zr-DFO-MSTP2109A Anti-STEAP1 AntibodyJorge A Carrasquillo, Bernard M Fine, Neeta Pandit-Taskar, et al.
JCO Precision Oncology|July 12, 2021
Differential Impact of ALK Mutations in NeuroblastomaTara O'Donohue, Nitya Gulati, Audrey Mauguen, et al.
Pediatric Blood & Cancer|August 29, 2025
A Single Institutional Experience Using Romiplostim to Treat Therapy-Related Thrombocytopenia in Pediatric Solid Tumor PatientsMelanie D Degliuomini, Katherine Armstrong, Michael Curry, et al.
Frontiers in Oncology|January 23, 2023
Skeletal muscle metastases in neuroblastoma share common progenitors with primary tumor and biologically resemble stage MS diseaseChristina Fong, Brian H Kushner, Angela Di Giannatale, et al.
Oncotarget|December 2, 2015
Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoinBrian H Kushner, Irina Ostrovnaya, Irene Y Cheung, et al.
Molecular Pharmaceutics|May 24, 2019
Pharmacokinetics and Biodistribution of a [89Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer PatientsJoseph A O'Donoghue, Daniel C Danila, Neeta Pandit-Taskar, et al.
Journal of Pediatric Surgery|December 15, 2015
Salvage rates after progression of high-risk neuroblastoma with a soft tissue massJennifer M Murphy, Irene-Isabel P Lim, Benjamin A Farber, et al.
Pediatric Blood & Cancer|February 17, 2005
Long-term complications in survivors of advanced stage neuroblastomaCaroline Laverdière, Nai-Kong V Cheung, Brian H Kushner, et al.
International Journal of Cancer|March 26, 2018
Treatment and outcome of adult-onset neuroblastomaMaya Suzuki, Brian H Kushner, Kim Kramer, et al.
Oncotarget|December 10, 2017
MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapyBrian H Kushner, Michael P LaQuaglia, Shakeel Modak, et al.
Pageof 30